ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy Jason R. Westin , Alex F. Herrera , Ryan Lynch , Jeremy S. Abramson , Don A. Stevens , Matthew Matasar , Lindsey Fitzgerald , Alan P Skarbnik , Chaitanya Iragavarapu , James H Essell , Bradley D. Hunter , Akil Merchant , Indumathy Varadarajan , Anand Tandra , Edward Licitra , Locke Johnson Bryan , Rushang D. Patel , Rajesh Behl , Jeff P. Sharman , Houston Holmes , Habte A. Yimer , Mitul Gandhi , Nosha Farhadfar , Nancy L. Bartlett , Michael Leukam , Tahir Latif , Paolo Caimi , Jean Yared , Amy Feng , Lynn Navale , Sri Ghatta , John B. Le Gall , Zachary J Roberts , John M. Burke Blood（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
